New Delhi, February 16 Drug firm Lupin announced on Monday that it has signed a licensing and supply agreement with Spektus Pharma to commercialize the novel antidepressant DeslaFlex in Canada.
The strategic partnership combines Lupin's strong commercial presence in Canada and Spektus's capabilities in developing differentiated, novel formulations to successfully introduce DeslaFlex and establish a robust platform for future launches.
The collaboration further strengthens Lupin's CNS portfolio with physician-endorsed, value-added therapies, well aligned with a supportive regulatory environment.
"The addition of DeslaFlex to our portfolio provides patients and clinicians with much-needed flexibility in the management of Major Depressive Disorder, enabling clinicians to deliver more personalized, patient-focused care," said Claus Jepsen, President, Global Specialty, Lupin.
Spektus Pharma CEO Zarvaan Merchant said Lupin's global brand and established commercial strength in Canada make it an ideal partner to realize the full value of DeslaFlex for patients in this important market. Lupin shares on Monday ended 0.97 per cent up at Rs 2,220.50 apiece on BSE.